Our group aims to develop new T-cell based concepts for cancer immunotherapy that overcome the major challenge of self-tolerance in cancer. To this end, one of our main strategies involves studies of how the immune system from healthy donors can target patient cancer cells. We have a strong focus on the development of new technologies that allow high-throughput identification of therapeutic targets that can evoke immune responses, as lack of immunogenic targets represents a major limitation in therapeutic efficacy. The group furthermore has a strong translational focus and performs penetrating mechanistic analyses in clinical trials together with our clinical partners. The group is a member of K.G. Jebsen Center for Cancer Immunotherapy (Center Director: Olweus).
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
MAbs, 12 (1), 1795505
Finding Neo (antigens, that is)
Blood, 134 (2), 108-109
Induction of neoantigen-reactive T cells from healthy donors
Nat Protoc, 14 (6), 1926-1943